Clinical Trial Update: This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). [Phase 3]

View source ↗

Summary

This clinical trial update reports Phase 3 results evaluating two dose regimens of secukinumab for efficacy and safety in moderate-to-severe hidradenitis suppur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hidradenitis Suppurativa | Phase 3 | Status: COMPLETED | Results posted: 2024-09-25